Joined in 2023 
82 
63 About this deal
Rowatinex® contains glycerine (glycerol) which is harmful in high doses. It may cause headache, stomach upset and diarrhoea. This medicine maycause allergic reactions (possibly delayed) as it contains sodium ethylhydroxybenzoate (E215) and sodium propyl hydroxybenzoate (E217). 3.How to take Rowatinex® Colica renala severa, anurie, infectii grave ale tractului urinar, litiaza urinara care necesita tratament chirurgical. function e(){var e=document.createElement('script');e.type='text/javascript',e.async=true,e.src='//staticw2.yotpo.com/MCN0waWlSaGnmquVBtpvetg2aznN9nNnQb9m8rPf/widget.js';var t=document.getElementsByTagName('script')[0];t.parentNode.insertBefore(e,t)})(); Trebuie avute in vedere precautii la pacientii tratati cu anticoagulante sau alte medicamente metabolizate la nivel hepatic care au un indice terapeutic mic. There is no information available regarding the safety of this medicine for use during pregnancy. It is not recommended for use in pregnancy, particularly during the first trimester. Seek further medical advice from your doctor.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required.These measures will help to protect the environment. 6. Further information Thuốc không nên dùng ở những bệnh nhân bị đau bụng nặng, ít nước tiểu hoặc nhiễm trùng đường tiết niệu nặng. For Adults: Take 1 tablet / time x 3 - 4 times / day For children: Depending on the age of the child, there will be corresponding doses of Rowatinex, if the child is between 6 and 14 years old, it is usually indicated. 1 tablet/time x 2 times/day Note that when taking Rowatinex, it must be taken before meals, swallowed whole and do not chew. In addition, many recommendations suggest that patients should drink plenty of water while taking Rowatinex, specifically about 4-5 liters of water/day.Before a drug is prescribed, the patient will be examined for the current medical condition as well as taking the patient's history to be able to give a suitable dose for each different group of subjects:
Should not be used in patients receiving oral anti-coagulants or other drugs metabolised by the liver where dose is critical. 4.6 Pregnancy and lactation ROWATINEX has spasmolytic action promoting the passage of stones in the tracts and reducing the pain of renal and ureteric colics. ROWATINEX has ahyperaemic effect and reduces Inflammatory effects. Doza uzuala este de 3-5 picaturi orale, solutie Rowatinex de 4-5 ori pe zi, cu 30 de minute inainte de mese sau conform recomandarii medicului.The exact mechanism of action of Rowatinex is not yet fully known. In preclinical experiments, it was confirmed that Rowatinex has antilithogenic, antibacterial, anti-inflammatory, spasmolytic, and analgesic properties [ 14, 15]. The antilithogenic property, which influences renal oxalate lithogenesis, is important because most urinary stones are composed of calcium oxalate aggregates. Inhibition of remnant stone formation originating after SWL might increase the long-term success rate of SWL [ 16]. In addition, Rowatinex has shown antibacterial effects against a variety of pathogens [ 10]. Rowatinex has anti-inflammatory and analgesic properties derived from cineole and anethole, which are important to patients who have urolithiasis with spasm, inflammation, pain, and infection [ 17, 18]. According to Horvath [ 19], Rowatinex and its single terpenes-such as camphene, cineole, and borneol- have antispasmodic effects on smooth muscle preparations in animal models. Djaladat et al. [ 7] reported that Rowatinex increases urine excretion by increasing renal blood flow and has antispasmodic effects that may help with the expulsion of renal stone. Engelstein et al. [ 11], in their prospective, randomized, and double-blind study, showed that the expulsion rate of ureteral stones in the Rowatinex group was greater than that in the placebo group in 87 patients in the emergency room (81% compared with 59%). However, the number of subjects in that study was small, and the authors did not consider stone size and treatment duration. In a randomized trial conducted by Romics et al. [ 10], the expulsion rate of urinary stones was greater and the treatment duration was shorter in the Rowatiex group than in the placebo group; no significant differences in age, sex, or stone size were found between the two groups. The expulsion rate of urinary stones 2 weeks after the initial SWL was not significantly different between the two groups (37.4% compared with 35.5%, p=0.684). However, 4 weeks after the initial SWL, the cumulative expulsion rate of ureteral stones in group 1 was greater than that in group 2 (72.2% compared with 61.1%, p=0.022). This result indicates that Rowatiex was not effective at stone expulsion in the short term, but was effective over a treatment period of 4 weeks. script>